Source: GlobeNewswire

Press Release: Paratek : Paratek Pharmaceuticals Generates Net Revenues of $3.9 Million in the Third Quarter of 2019

-- Third Quarter 2019 NUZYRA® (omadacycline) Net Sales increased 82% versus the Prior Quarter to $3.1 Million ---- Oral-only CABP Pharmacokinetics Study Initiated--

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
Evan Loh's photo - CEO of Paratek


Evan Loh

CEO Approval Rating


Paratek is a biopharmaceutical company that develops antibiotic drugs to treat bacterial pneumonia in adults. Read more